New Immunotherapy Cancer Treatment Empliciti (Elotuzumab) For Multiple Myeloma

Empliciti (Elotuzumab) is an FDA approved immunotherapy treatment for multiple myeloma cancer. Medical oncologist Dr. Stephen Lemon talks about how this new cancer drug treatment works as well as what types of side effects it may cause.

Empliciti is developed by Bristol-Myers Squibb. Dr. Stephen Lemon is a medical oncologist and is not affiliated with Bristol-Myers Squibb.